Posted by Michael Wonder on 26 Jul 2023
Mirum’s Livmarli now authorised in Canada for cholestatic pruritus in patients with Alagille syndrome
25 July 2023 - Approval supported by more than six years of Livmarli data demonstrating improvements in pruritus and serum bile acids.
Mirum Pharmaceuticals today announced that Livmarli (maralixibat oral solution) has been authorised by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome.
